$OMDA

Omada Health, Inc. (OMDA): Results of Operations and Financial Condition

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch

Original reporting
Published Aug 6, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$OMDA
Bullish
medium confidence
Mentioned
$OMDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OMDABullishHigh
01

Why it matters

Traders can reprice the stock based on raised revenue and adjusted EBITDA ranges plus margin expansion, while monitoring execution risk around leadership handoff and commercial rollout (including cholesterol management).

02

Market read

Raised FY 2026 revenue and adjusted EBITDA guidance, record gross margins, and a scheduled CEO transition create a fresh catalyst set for positioning into the next earnings cycle.

03

What to watch

The filing does not provide net loss outlook or GAAP-to-non-GAAP reconciliation, leaving uncertainty around GAAP profitability and warrant-related items.

Relevance 7/10Novelty 9/10Timing: after-hours filing and same-day conference call (Aug 6, 2026)

Background

Omada Health filed an 8-K with Q2 2026 operating results, an updated full-year outlook, and a planned CEO transition effective Jan 1, 2027.

Company-level read

Ticker impact

$OMDABullishMedium confidence
Context

Omada reported Q2 2026 results and raised full-year outlook, with revenue $88M (+43% YoY) and adjusted EBITDA $11M, plus CEO transition effective Jan 1, 2027.

Expected impact

Near-term bias to the upside on guidance/margin leverage, with volatility around the CEO transition narrative and any follow-through on 2027 revenue from new customers.

Evidence & confidence

The filing discloses fresh, decision-relevant datapoints: quarterly financials, raised FY revenue and adjusted EBITDA ranges, and a scheduled executive transition with defined roles and effective date.

Market effects

Improving margins and member growth in virtual care can support sentiment for digital health and chronic-care platforms, though impact is company-specific.

Primarily US-focused commercial expansion and PBM partnerships; limited direct regional spillover.

Low global relevance beyond investor sentiment for US-listed digital health providers.

Counterpoint

Guidance strength may be partially driven by non-GAAP profitability and member growth that could face churn or reimbursement pressure, so upside may not persist.

Key entities

  • Omada Health, Inc.

    Nasdaq-listed virtual between-visit healthcare provider reporting Q2 2026 results and raised FY 2026 outlook, with CEO transition planned for Jan 1, 2027.

  • Wei-Li Shao

    President becoming CEO effective Jan 1, 2027, responsible for strategy and operations.

  • Sean Duffy

    Co-founder and CEO transitioning to Founder and Executive Chair effective Jan 1, 2027.

  • Jeryl Hilleman

    Board Chairperson becoming Lead Independent Director and continuing as Audit Committee Chair effective Jan 1, 2027.

Related articles

$OMDAHighAI 9/10

Omada Health (OMDA) Q2 2026 Earnings Call Transcript

Omada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.

$LULUMed

JPMorgan resets Lululemon stock price target by 38%

JPMorgan cut Lululemon's (LULU) price target by 38% to $95, citing weak Q2 results and lower guidance. Revenue fell 4% to $2.4B, with North America and China sales declining. LULU stock is down 80% from highs. Boss maintained a 'Neutral' rating, noting challenges and high marketing costs.

$SUPVMed

Supervielle (SUPV) Swings Back To Profit As Layoffs Reshape The Bank

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.

$DELLHighAI 9/10

Dell Stock Jumped 15% Last Week. Here's Why This Top AI Stock Is Still a Buy

Dell's stock rose 15% after reporting a 58% revenue increase to $47B, driven by AI infrastructure demand. AI-optimized server sales doubled to $16.4B, and traditional server revenue surged 122% to $10.5B. Adjusted earnings per share rose 203% to $7.04. Dell raised its full-year guidance, expecting 69% revenue growth to $192B and 148% earnings growth to $25.50 per share.

$GRNTMed

Granite Ridge (GRNT) Grows Profits While Costs Quietly Creep Higher

Granite Ridge Resources (GRNT) reported Q2 net income of $30M ($0.23/share), up from $25.1M a year ago, with production rising 1% to 32,044 Boe/d. The company added 21.9 net undeveloped locations via acquisitions and declared a $0.11/share dividend. Adjusted EBITDAX increased to $79.6M, but lease operating expenses rose 47% per barrel to $10.27. Oil prices rose, while natural gas prices fell.